LY4268989

LY4268989, originally MORF-057 and now carrying the INN zotemtegrast [10], is Eli Lilly's bet on turning the Entyvio playbook into a pill. The drug is an oral small-molecule inhibitor of α4β7 integrin, the same gut-selective immune receptor hit by Takeda's infused antibody vedolizumab, which generates roughly $6 billion in annual revenue [8]. Lilly paid about $3.2 billion to acquire Morphic Holding in 2024 to pick up this asset [1], primarily on the strength of the small open-label EMERALD-1 Phase 2a readout. The placebo-controlled EMERALD-2 Phase 2b readout that followed in late 2024 to 2025 was characterized by independent IBD commentators as a near miss, with the drug hitting its primary endpoint numerically but confronting a higher-than-expected placebo response that compressed the placebo-adjusted delta [11]. The compound is now the lead candidate across multiple Phase 2 trials in moderate-to-severe ulcerative colitis, including a 1,431-patient monotherapy study [2] and a 252-patient combination trial with mirikizumab (TOPAZ-UC) [3], plus a parallel 385-patient Crohn's disease trial, GARNET [12].

Novel oral compound, in Phase 2 across both ulcerative colitis (UC) and Crohn's disease. No FDA designations have been publicly granted. EMERALD-1 (NCT05291689), the original Phase 2a open-label single-arm study, enrolled 35 moderate-to-severe UC patients and reported a 25.7% clinical remission rate by modified Mayo score (mMCS) and 45.7% clinical response at week 12 [4]. These are the data that supported Lilly's acquisition. Note that EMERALD-1 had no placebo arm, so the headline remission number is not placebo-adjusted. The Phase 2b placebo-controlled follow-up, EMERALD-2 (NCT05611671), enrolled 280 patients across three MORF-057 arms (100 mg twice daily, 200 mg twice daily, and a once-daily dose) plus placebo, with 12 weeks of induction followed by a 40-week maintenance period [13]. Primary completion was November 2024, with topline results reported through 2025 and presented at UEG Week 2025. Public commentary characterized the readout as a near miss: primary endpoint of clinical remission by mMCS at week 12 was numerically favorable but the placebo arm overperformed expectations, narrowing the placebo-adjusted delta [11]. Lilly has nonetheless pushed forward with two larger Phase 2 programs now recruiting. NCT07415044 is the 1,431-patient monotherapy study whose readout will anchor the Phase 3 decision [2]. NCT07186101 (TOPAZ-UC) is the 252-patient combination study pairing LY4268989 with mirikizumab (Omvoh), testing whether blocking α4β7 trafficking and IL-23 signaling together drives deeper remission [3]. In Crohn's disease, GARNET (NCT06226883) is a 385-patient Phase 2 placebo-controlled study of three dose regimens that began enrolling in July 2024 and is scheduled to run through 2030 [12]. Two Phase 1 pharmacokinetic studies in healthy volunteers (NCT06964776, NCT07707375) remain active, suggesting Lilly is still optimizing dose and food-effect data before pivotal work [5][6]. Lilly's 2025 10-K lists Morphic integration as a core piece of the immunology pipeline alongside mirikizumab [7]. A Phase 3 program has not been publicly announced with a start date, but given the acquisition economics and the competitive clock in UC, a 2027 Phase 3 initiation after the NCT07415044 induction readout is the most plausible path.

The target is α4β7, a protein pair sitting on the surface of certain T cells that acts like a GPS address for the gut. These T cells carry α4β7 and dock onto MAdCAM-1, a matching protein expressed by blood vessels specifically in gut tissue. Dock, roll out of circulation, enter the gut wall, drive inflammation. In ulcerative colitis this traffic is on overdrive and the colon lining gets chewed up. Block the α4β7-MAdCAM-1 handshake and inflammatory T cells get kept out of the gut without broadly suppressing immunity elsewhere. This mechanism is as validated as it gets in IBD. Takeda's vedolizumab (Entyvio) is a monoclonal antibody against α4β7, approved in both UC and Crohn's disease, and generated roughly $6 billion in recent annual revenue [8]. The vedolizumab clinical story is clean: it works, it is gut-selective, and because it does not touch α4β1 in the brain the way the older drug natalizumab does, it has not carried a progressive multifocal leukoencephalopathy (PML) warning. PML is a frequently fatal brain infection caused by reactivation of the JC virus, a common polyomavirus that lies dormant in a majority of healthy adults. Natalizumab's broader integrin blockade appears to open the door for JC virus to escape immune surveillance in the central nervous system, which is why its label carries a black box warning. The open question for LY4268989 is not whether α4β7 is a good target. It is whether an oral small molecule can occupy enough of the receptor long enough to match an infused antibody. Prior oral α4β7 inhibitors, notably Japan-approved carotegrast methyl (AJM300), produced only modest clinical remission numbers [9]. LY4268989 was engineered with higher potency and selectivity to clear that bar.

A note on terminology: induction refers to the first 8 to 12 weeks of treatment, when the drug has to demonstrate it can push an actively flaring colon into clinical remission. Maintenance is the longer tail that follows, testing whether remission holds through a year or more. UC regulatory packages typically require evidence of both. The lead UC Phase 2 is NCT07415044, structured with late-stage-scale enrollment of 1,431 adults with moderate-to-severe UC [2]. Primary endpoint is the percentage of patients achieving clinical remission by modified Mayo score at the end of induction. A trial that large at Phase 2 is unusual, and typically signals one of two things: Lilly is running what is effectively a seamless Phase 2 to Phase 3, or hedging against a modest effect size with statistical power. The EMERALD-2 near-miss context makes the second interpretation more plausible. Comparator is placebo, standard for induction in UC. NCT07186101 (TOPAZ-UC), the combination study with mirikizumab, is smaller (n=252) and more mechanistically interesting [3]. It tests whether adding α4β7 blockade to IL-23 blockade produces deeper remission than mirikizumab alone, which is the open question in UC: can combinations finally break the 30 to 40 percent ceiling monotherapies hit on endoscopic healing? EMERALD-1 (NCT05291689), the original Morphic Phase 2a monotherapy study, was a 35-patient open-label single-arm trial that provided the proof-of-concept data supporting Lilly's acquisition [4]. The follow-up EMERALD-2 (NCT05611671) was the first placebo-controlled test, with 280 patients randomized to 100 mg BID, 200 mg BID, QD MORF-057, or placebo, with 12-week induction followed by 40 weeks of maintenance [13]. Full data from the maintenance phase and the detailed dose-response are the key translational package. In Crohn's disease, GARNET (NCT06226883) is Lilly's parallel Phase 2 program, 385 patients across three MORF-057 doses plus placebo [12]. Vedolizumab's dual UC/CD approval is the roadmap. A Crohn's win would double the addressable franchise. Enrollment status across active trials appears healthy per registry updates, with recruiting status reaffirmed in 2025 and 2026. The combination design is the readout to watch, because a positive result reshapes UC algorithms by establishing combination immunology as a plausible standard for moderate-to-severe disease.

Our model estimates a 17% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 30%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase, more secondary endpoints than usual, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest. The question is not whether α4β7 blockade works in UC. It is whether an oral pill can match an infusion. Receptor occupancy with oral integrin inhibitors is notoriously choppy because the drug has to clear the gut wall, enter circulation, bind a receptor on circulating lymphocytes, and stay bound through peaks and troughs. EMERALD-2's higher-than-expected placebo response is the current head wind: even if the drug is pharmacologically doing what it should, modern UC trial populations have become harder to beat on placebo-adjusted endpoints as advanced therapies have pulled the sickest patients out of the enrollment pool. If placebo-adjusted remission in NCT07415044 lands at 5 to 8 percentage points, the drug is a commercial also-ran even if it technically works. Safety risk is lower than for the broader α4 class. Natalizumab, which blocks α4β1 as well as α4β7, carries a PML black box warning because it enables JC virus reactivation in the central nervous system. LY4268989 is designed as a selective α4β7 inhibitor, so the PML risk is theoretically much lower, matching the vedolizumab safety profile. But long-term oral exposure with small molecules can surface off-target issues that short Phase 1 and Phase 2 studies miss. No clean liver, cardiac, or infection signals have been publicly reported from EMERALD-1 or EMERALD-2 as of 2026. Execution risk centers on the 1,431-patient trial design. Running a Phase 2 that large pushes timelines and increases placebo variability. Enrollment pace in UC trials has slowed since 2023 as the competitive field crowds the same patient pool. Commercial risk is sharp. UC in 2026 already has JAK inhibitors (upadacitinib, oral small molecules that broadly dial down intracellular inflammatory signaling), S1P modulators (etrasimod and ozanimod, oral drugs that trap lymphocytes in lymph nodes rather than letting them traffic to the gut), IL-23 inhibitors (risankizumab and mirikizumab, biologics that block a cytokine driving Th17 inflammation), and vedolizumab itself. An oral α4β7 needs to be clearly better than one of those on efficacy, safety, or convenience to earn payer coverage. Oral dosing alone is table stakes against upadacitinib and etrasimod, which are already orals in the same market.

Worth watching, with specific triggers. The signal to look for is full data from NCT07415044, specifically placebo-adjusted clinical remission at week 12 and endoscopic improvement at week 52. Based on enrollment start timing, 12-week induction windows, and standard UC Phase 2 timelines for a trial this size, the induction readout is most plausibly a late-2027 to 2028 event, with maintenance data a year later. Numbers worth caring about: placebo-adjusted remission above 15 percentage points puts this drug in the vedolizumab zone and makes it the first credible oral α4β7 globally. Below 10 points and the thesis unravels, because EMERALD-2 already showed what a weak delta looks like and Lilly has an IL-23 franchise with mirikizumab plus orals coming across the broader IBD class. The combination trial with mirikizumab (NCT07186101, TOPAZ-UC) is the sleeper. If α4β7 plus IL-23 blockade produces deeper remission than either alone, Lilly has a differentiated story no competitor can match with a single asset, because no other company owns both targets. That readout, likely 2027 to 2028 given the smaller 252-patient design, is the biggest commercial lever for this program. The Crohn's GARNET readout (NCT06226883) is the quietest lever but a real one. Vedolizumab in CD generated meaningful revenue beyond its UC franchise. If LY4268989 shows activity in Crohn's at similar levels to UC, the commercial case expands materially even if the UC placebo-adjusted number stays modest. The realistic Phase 3 trigger: Lilly needs placebo-adjusted mMCS remission of roughly 12 to 15 percentage points from NCT07415044 to justify a pivotal UC monotherapy program. A soft readout likely redirects spend into the combination strategy with mirikizumab. A clearly weak readout invites impairment of some portion of the $3.2 billion Morphic goodwill. Check back around major GI meetings (DDW in May, UEG Week in October) for Phase 2 full data. Lilly's annual 10-K reporting on Morphic integration will quantify how much of the $3.2 billion acquisition cost stays capitalized versus written down, a soft indicator of internal confidence [7]. Patent protection on the composition of matter is held by Lilly through acquisition from Morphic, but published expiry details are not easily verifiable in open sources and should not be used for exclusivity-horizon modeling without an original patent-office search. Lilly's broader play is to own both IBD and obesity as high-margin oral franchises. LY4268989 is the IBD leg. The strategy fits. A name to watch for readouts, not a name to buy on hope.